2006
DOI: 10.1038/sj.onc.1209982
|View full text |Cite
|
Sign up to set email alerts
|

Inhibitors of NF-κB signaling: 785 and counting

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
497
0
3

Year Published

2006
2006
2018
2018

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 546 publications
(515 citation statements)
references
References 165 publications
5
497
0
3
Order By: Relevance
“…NF-κB1 (p105/p50) and NF-κB2 (p100/p52) need to be processed to become active and translocate to the nucleus where they associate with RelA (p65), c-Rel and RelB in different hetero-and homodimers to form the transcriptionally active complex. 16 Mice deficient in RelB show reduced numbers of MZ B cells, 17 whereas mice lacking a negative regulator of NF-κB have more MZ B cells 18 similar to mice that lack the inhibitory p100 subunit of NF-κB2. 19 We therefore quantified the abundance of all NF-κB proteins in the cytosol and the nucleus by immunoblotting of subcellular fractions obtained from freshly isolated splenocytes.…”
Section: Resultsmentioning
confidence: 99%
“…NF-κB1 (p105/p50) and NF-κB2 (p100/p52) need to be processed to become active and translocate to the nucleus where they associate with RelA (p65), c-Rel and RelB in different hetero-and homodimers to form the transcriptionally active complex. 16 Mice deficient in RelB show reduced numbers of MZ B cells, 17 whereas mice lacking a negative regulator of NF-κB have more MZ B cells 18 similar to mice that lack the inhibitory p100 subunit of NF-κB2. 19 We therefore quantified the abundance of all NF-κB proteins in the cytosol and the nucleus by immunoblotting of subcellular fractions obtained from freshly isolated splenocytes.…”
Section: Resultsmentioning
confidence: 99%
“…For instance, inhibition of NF-κB activity due to elevated Nfkbia expression across many tissue types appears to be a common response to CR. At least one proposed CR-mimetic compound, resveratrol, mimics this effect (Manna et al, 2000;Pendurthi et al, 2002;Iyori et al, 2008), and similar responses might also be attained by treatment with other NF-κB inhibitors now undergoing development (Gilmore and Herscovitch, 2006).…”
Section: Discussionmentioning
confidence: 95%
“…To our knowledge, none of the many NF-kB signaling inhibitors described so far (Gilmore and Herscovitch, 2006) have been shown in vivo to increase chemotherapy efficiency in CRC. Taken together, our results provide a rationale for using the IKK2 inhibitor AS602868 combined with CPT-11 as a promising therapeutic strategy for clinical testing in CPT-11 refractory CRC and probably other solid tumours.…”
Section: Discussionmentioning
confidence: 98%